The largest drugmaker within Britain, GlaxoSmithKline, has been hit with the latest in a serious of multinational controversies regarding so-called pay-for-delay deals, used when drugmakers pay the producers of generic drugs to keep their products, often less expensive than brand-names, off the shelves. GSK had reportedly defended its business practices and denied any wrongdoing, but the Office of Fair Trading has accused the company of abusing its market dominance by paying the makers of the generic form of antidepressant Seroxat to delay the sale of their version of the drug. According to the OFT, GSK is accused of colluding with Alpharma, Gerics and Norton Healthcare over the supply of the drug about 10 years ago. The supply agreements were reportedly terminated in 2004. Similar investigations have been initiated within the US and Europe.
Full Content: Euronews
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Partially Dismisses Investor Suit Against Google Over Ad Practices
Mar 25, 2025 by
CPI
UK Watchdog Scrutinizes Ticketmaster’s Dynamic Pricing Amid Oasis Ticket Controversy
Mar 25, 2025 by
CPI
Democratic Senators Urge White House to Seek Congressional Approval for TikTok Deadline Extension
Mar 25, 2025 by
CPI
Spain’s Antitrust Authority Probes Generali and Sanitas Over Competition Concerns
Mar 25, 2025 by
CPI
EU Lawmakers Warn Against Weakening AI Regulations
Mar 25, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mobile Ecosystems
Mar 24, 2025 by
CPI
Mobile Ecosystems: An Intellectual Entelechy but A Necessary Model
Mar 24, 2025 by
Alba Ribera Martinez
Creating Contestability and Fairness in Mobile Ecosystems: The Contribution of the DMA
Mar 24, 2025 by
Damien Geradin & Daniel Mandrescu
Digital Ecosystems and the Not (Yet) As Efficient Competitor Principle
Mar 24, 2025 by
Thomas Hoppner & Philipp Westerhoff
Assessing the Competition Law Scrutiny of Smart Wearables and Mobile AR/VR Devices
Mar 24, 2025 by
Kayvan Hazemi-Jebelli